Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.1093/ofid/ofab163
![](/digitum/image/email_logo.png)
![](/digitum/image/logo-facebook.png)
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Escrihuela-Vidal, Francesc | - |
dc.contributor.author | López-Cortés, Luis Eduardo | - |
dc.contributor.author | Escolà-Vergé, Laura | - |
dc.contributor.author | Alarcón González, Arístides de | - |
dc.contributor.author | Cuervo, Guillermo | - |
dc.contributor.author | Sánchez-Porto, Antonio | - |
dc.contributor.author | Fernández-Hidalgo, Nuria | - |
dc.contributor.author | Luque, Rafael | - |
dc.contributor.author | Montejo, Miguel | - |
dc.contributor.author | Miró, José M. | - |
dc.contributor.author | Goenaga, Miguel Ángel | - |
dc.contributor.author | Muñoz, Patricia | - |
dc.contributor.author | Valerio, Maricela | - |
dc.contributor.author | Ripa, Marco | - |
dc.contributor.author | Sousa-Regueiro, Dolores | - |
dc.contributor.author | Gurguí, Mercé | - |
dc.contributor.author | Fariñas-Álvarez, María Carmen | - |
dc.contributor.author | Mateu, Lourdes | - |
dc.contributor.author | García-Vázquez, Elisa | - |
dc.contributor.author | Gálvez-Acebal, Juan | - |
dc.contributor.author | Carratalà, Jordi | - |
dc.contributor.author | Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) | - |
dc.contributor.author | Barcelona Endocarditis Study Team (BEST) | - |
dc.contributor.other | Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Medicina Interna | es |
dc.date.accessioned | 2024-06-26T08:40:05Z | - |
dc.date.available | 2024-06-26T08:40:05Z | - |
dc.date.issued | 2021-03-25 | - |
dc.identifier.citation | Open Forum Infectious Diseases, Volume 8, Issue 6, June 2021, ofab163 | es |
dc.identifier.issn | Electronic: 2328-8957 | - |
dc.identifier.uri | http://hdl.handle.net/10201/142707 | - |
dc.description | ©2021 he Author(s). Oxford University Press . This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/. This document is the Published, version of a Published Work that appeared in final form in Open Forum Infectious Diseases. To access the final edited and published work see https://doi.org/10.1093/ofid/ofab163 | es |
dc.description.abstract | Background. Although Streptococcus anginosus group (SAG) endocarditis is considered a severe disease associated with abscess formation and embolic events, there is limited evidence to support this assumption. Methods. We performed a retrospective analysis of prospectively collected data from consecutive patients with definite SAG endocarditis in 28 centers in Spain and Italy. A comparison between cases due to SAG endocarditis and viridans group streptococci (VGS) or Streptococcus gallolyticus group (SGG) was performed in a 1:2 matched analysis. Results. Of 5336 consecutive cases of definite endocarditis, 72 (1.4%) were due to SAG and matched with 144 cases due to VGS/ SGG. SAG endocarditis was community acquired in 64 (88.9%) cases and affected aortic native valve in 29 (40.3%). When comparing SAG and VGS/SGG endocarditis, no significant differences were found in septic shock (8.3% vs 3.5%, P = .116); valve disorder, including perforation (22.2% vs 18.1%, P = .584), pseudoaneurysm (16.7% vs 8.3%, P = .108), or prosthesis dehiscence (1.4% vs 6.3%, P = .170); paravalvular complications, including abscess (25% vs 18.8%, P = .264) and intracardiac fistula (5.6% vs 3.5%, P = .485); heart failure (34.7% vs 38.9%, P = .655); or embolic events (41.7% vs 32.6%, P = .248). Indications for surgery (70.8% vs 70.8%; P = 1) and mortality (13.9% vs 16.7%; P = .741) were similar between groups. Conclusions. SAG endocarditis is an infrequent but serious condition that presents a prognosis similar to that of VGS/SGG. | es |
dc.format | application/pdf | es |
dc.format.extent | 7 | es |
dc.language | eng | es |
dc.publisher | Oxford University Press | es |
dc.relation | This work was supported by Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0005), co‐financed by the European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. We thank CERCA Programme/Generalitat de Catalunya for institutional support. J. M. M. received a personal 80:20 research grant from Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–2021 | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Infective endocarditis | es |
dc.subject | Streptococcus anginosus | es |
dc.subject | Viridans group streptococci | es |
dc.subject | Streptococcus gallolyticus | es |
dc.title | Clinical features and outcomes of streptococcus anginosus group Infective endocarditis: A multicenter matched cohort study | es |
dc.type | info:eu-repo/semantics/article | es |
dc.relation.publisherversion | https://academic.oup.com/ofid/article/8/6/ofab163/6199901?searchresult=1 | es |
dc.identifier.doi | https://doi.org/10.1093/ofid/ofab163 | - |
Aparece en las colecciones: | Artículos: Medicina |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Clinical Features and Outcomes of Streptococcus anginosus....pdf | 167 kB | Adobe PDF | ![]() Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons